UnitedHealth Group IncorporatedNYSE: UNH
Health Care · Managed Health Care
$408.67
-0.58%
Vol: 1.2M
Research Digest
Tuesday, June 16, 2026
No significant overnight updates
No material news in the last 48 hours.
Previous Market Intelligence
13 daysJun 15No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 14UnitedHealth jumps 5% on improving-prospects optimism as JPMorgan lifts target and company launches AI care chatbot AveryPositive▶
UnitedHealth shares surged 5.2% amid growing optimism about the health insurer's improving prospects, trading around $405-$409. JPMorgan raised its price target to $466 from $420 and kept an Overweight rating. The company introduced Avery, an AI healthcare chatbot designed to coordinate care for members, and is seeing positive momentum from multiple analyst upgrades and a proposed insulin-pricing settlement. Optum Rx also said it will align pharmacy payment models more closely to manufacturer pricing actions by January 2028. UnitedHealth will report Q2 2026 results on July 16, 2026 before market open. The stock trades at ~30.8x earnings with a ~2.2% yield. The risk is that despite the rally, the broader analyst average 12-month target (~$407) sits near the current price, suggesting much of the optimism may already be priced in ahead of earnings.
May 21UnitedHealth shares fell as Berkshire Hathaway fully exited its ~5M share UNH position in Q1 (disclosed May 15 13F); UNH closed at $391.13 on May 18.Mixed▶
Berkshire Hathaway disclosed in its May 15 13F that it fully exited its UnitedHealth position in Q1 2026 (less than a year after revealing the stake in August 2025). UNH shares fell in early trading May 18, closing at $391.13. Analysts attribute the move to Berkshire leadership transition rather than a fundamental negative view. Operationally, UnitedHealthcare cut prior authorization requirements by 30% (May 5), Optum Rx introduced the industry's first transparent pharmacy care model (May 11), and Bloomberg reported (May 15) that UnitedHealth is tracking employee AI usage in Optum services. Stock remains up ~20% YTD with 22 Buy/1 Sell ratings.
May 20UnitedHealth falls more than 2% after Berkshire Hathaway disclosed full exit of its UNH stake in Q1 13FMixed▶
UNH shares fell over 2% on May 18 after Berkshire Hathaway revealed in a May 15 filing that it had fully sold its UnitedHealth stake during Q1 portfolio reshuffling. The stock had just reached a 52-week high of $404.14 on May 13, with month-to-date gains near 30% and YTD ~21%. Fundamentals remain strong: Q1 2026 revenue of $111.7B (+2% YoY) and adjusted EPS of $7.23 beat the $6.76 consensus, with full-year guidance raised. UnitedHealthcare announced cuts of 30% to prior authorization requirements on May 5, and Optum Rx launched a transparent pharmacy care model on May 11. UnitedHealth confirmed it is the subject of DOJ criminal and civil probes into Medicare Advantage billing practices. Risk: regulatory/DOJ overhang and political pressure on PBM economics.
May 19UnitedHealth tracking employee AI use as Optum Rx launches transparent pharmacy model and prior authorizations cut 30%Mixed▶
Bloomberg reported May 15 that UnitedHealth Group is tracking how often employees use AI tools as part of a company-wide push to embed AI across operations, signaling an aggressive cost-and-productivity transformation. UnitedHealthcare announced on May 5 that it has cut prior authorization requirements by 30%, and Optum Rx introduced what it calls the industry's first transparent pharmacy care model on May 11. UNH shares traded as low as $375 intraday May 18 before closing at $398.80, with the stock up 9.6% over seven sessions. Q1 results posted April 21 showed 2% revenue growth and management raised 2026 adjusted EPS guidance to at least $18.25. Risk: ongoing antitrust scrutiny, Medicare Advantage risk-coding investigations, coverage denial scrutiny, and Berkshire Hathaway recently sold its entire stake amid rising medical costs.
May 18UnitedHealth said it is tracking employees' AI usage as part of a company-wide transformation, while shares retreated from a recent 52-week high to around $375 amid concerns about Berkshire's exit and Medicare pressures.Mixed▶
Bloomberg reported on May 15 that UnitedHealth Group is tracking how often some employees use AI tools as part of a sweeping push to embed the technology across operations — a notable management/operational signal as it tries to lower costs. Shares pulled back from a May 13 52-week high near $404 to roughly $375 by May 18, with weakness tied in part to Berkshire Hathaway's complete exit from its UNH stake, regulatory overhangs and Medicare margin pressures. On the positive side, UnitedHealthcare announced it is eliminating prior-authorization requirements for 30% of services (and 70%+ will move to a standardized submission process by year-end), and Optum Rx introduced a transparent pharmacy care model. Bank of America raised its target to $420 from $380 on May 13. Risk: regulatory and reimbursement pressure plus continued investor confidence questions.
May 15Optum Rx sues California over PBM transparency law as UnitedHealth hits 52-week high of $404 and Goldman adds UNH to Conviction ListPositive▶
On May 13, UnitedHealth's Optum Rx sued the state of California over a new PBM law, arguing it would raise employer plan costs by ~$1,800 per participant annually; the law applies to self-insured employer plans, insurers, and public plans. Optum Rx also unveiled a transparent fee-based PBM model launching in 2027 that removes spread pricing and shifts to per-member fees. UNH shares hit a 52-week high of $404.15, up ~30% over the past month and ~23% YTD, after Q1 revenue grew 2% YoY to $111.7B with adjusted EPS of $7.23 above consensus, and management raised FY26 adjusted EPS guidance to >=$18.25 (from >=$17.75). Goldman Sachs added UNH to its Conviction List; BofA raised its PT to $420 from $380. UnitedHealthcare is also eliminating ~30% of prior authorization requirements. Risk: state-level PBM regulation and Medicare Advantage cost trends.
May 14UnitedHealth hit 52-week high of $404.14 on May 13 after Optum Rx unveiled transparent fee-based pricing model and Goldman Sachs added UNH to U.S. Conviction Buy listPositive▶
UnitedHealth Group reached a 52-week high of $404.14 on May 13, 2026 and closed at $399.36, up ~47% from its March 2026 low of $270.59. On May 13, Optum Rx disclosed a new transparent, fee-based pricing model that decouples profits from drug prices, getting ahead of PBM reform legislation. On May 5, UNH announced it would eliminate prior authorization requirements for 30% of medical services by year-end, responding to regulatory and public backlash. Goldman Sachs added UNH to its U.S. Conviction Buy list citing a bottoming Medicare Advantage underwriting cycle. UNH cut MA membership by 1.3 million in 2026 to repair margins; medical care ratio improved to 83.9% from 84.8%. UNH is investing $1.5B in AI in 2026. Risk: ongoing DOJ antitrust investigations, False Claims Act litigation, and Medicaid margin pressures remain material overhangs.
May 13UnitedHealth rallies 4.3% to $396.39 on May 12 amid BofA Healthcare Conference; recovered 47%+ from March lows.Positive▶
UnitedHealth Group shares climbed 4.3% to $396.39 on May 12 and presented at the Bank of America Securities Health Care Conference. The stock has staged a remarkable recovery, soaring 47%+ from its March 27 low of $259 (vs. starting the year at $336). Q1 2026 results showed revenue rising 2% YoY to $111.7B, with reported EPS of $6.90 and adjusted EPS of $7.23, both above expectations. Medical Care Ratio improved to 83.9% in Q1 from 88.9% in the prior quarter. UnitedHealth cut Medicare Advantage membership by 1.3 million in 2026 to improve margins, and is rolling out a fee-based pharmacy benefit model through Optum Rx. 25 analysts maintain a Buy consensus rating.
May 12UnitedHealth Q1 2026 EPS of $7.23 beat the $6.65 estimate by 9% and lifted FY26 adjusted EPS guidance above $18.25; UNH also announced plans to remove prior authorization for 30% of services.Positive▶
UnitedHealth reported Q1 2026 revenue of $111.7B and adjusted EPS of $7.23, beating the $6.65 consensus by 9%, and raised FY 2026 adjusted EPS guidance to greater than $18.25 (vs prior $17.75). The company drew strong investor attention by announcing it will eliminate prior authorization requirements for 30% of healthcare services, easing administrative friction for physicians. UNH agreed to acquire Alegeus Technologies and completed the sale of the Optum UK business with $400M of net proceeds committed to the United Health Foundation. Shares rallied sharply (30-day return +20.15%, 90-day +33.65%), trading $376-$385 on May 12. Senior leaders are presenting at the BofA Securities Healthcare Conference on May 12. Consensus rating is Buy with average price target ~$378.
May 11UnitedHealth raises 2026 EPS guidance to at least $18.25 after Q1 beat, cuts prior authorization by 30%, completes Optum UK sale and launches $2B buybackPositive▶
UnitedHealth posted Q1 2026 revenues of $111.7B and EPS of $7.23, beating consensus. The company raised full-year EPS guidance to at least $18.25 and signaled double-digit growth through 2028. Medical Care Ratio improved to 83.9% from an expected 85.5%, signaling margin recovery. UNH is removing prior authorization for 30% of services now, targeting 60% by year-end 2026. UNH completed the sale of Optum UK and authorized at least $2B in stock buybacks by end of Q2. Shares are up ~24% over the past 30 days, trading near $384.
May 8JPMorgan raises UNH price target to $420; stock surged 36.9% in April amid Medicare boost.Positive▶
UnitedHealth Group received upgraded analyst coverage with JPMorgan raising its price target to $420 from $389. The stock surged 36.9% in April following a $13 billion Medicare boost. On May 1, UnitedHealth was added to Goldman Sachs' US Conviction List. The company reported strong Q1 2026 results with $111.7 billion revenue and is implementing operational improvements including eliminating prior authorization for 30% of healthcare services.
May 6UnitedHealth beats Q1 revenue estimates and raises FY2026 EPS guidance amid CEO succession announcement.Positive▶
UnitedHealth Group reported Q1 2026 results surpassing revenue and earnings expectations on April 21. The company raised its 2026 adjusted EPS outlook to at least $18.25 from at least $17.75 previously. CEO Andrew Witty is stepping down for personal reasons, with a new leader appointed to lead the health insurance arm. Goldman Sachs added UNH to its Conviction List with a $448 price target, implying 21.4% upside.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| UNHUNITEDHEALTH | $408.67 | -0.58% | +5.1% | 19.7x | 0.65 | $373.3B |
| ELVELEVANCE | $397.94 | -0.98% | +2.0% | 13.7x | 0.68 | $87.3B |
| HUMHUMANA | $377.00 | -0.86% | +24.3% | 24.2x | 0.77 | $45.7B |
| CNCCENTENE | $61.22 | -3.44% | +8.9% | 14.2x | 1.09 | $31.3B |
| MOHMOLINA | $202.82 | +0.47% | +9.2% | 21.8x | 0.80 | $10.5B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price above both MAs — bullish structure.